XELJANZ 5 MG 60 TABS

INDICATED FOR MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS (RA) IN ADULTS WITH AN INADEQUATE RESPONSE OR INTOLERANCE TO METHOTREXATE; MAY BE USED AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE OR OTHER NONBIOLOGIC DMARDS INDUCTION 10 MG PO BID FOR AT LEAST 8 WEEKS EVALUATE PATIENTS AND TRANSITION TO MAINTENANCE THERAPY DEPENDING ON THERAPEUTIC RESPONSE IF NEEDED CONTINUE 10 MG BID FOR MAXIMUM OF 16 WEEKS DISCONTINUE AFTER 16 WEEKS IF ADEQUATE THERAPEUTIC BENEFIT NOT ACHIEVED